Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune-evasive iPSC-derived cell therapies. Its core product is an iPS-T cell therapy platform designed to work with the patient’s immune system, built on a decade of research by co-founders Tobias Deuse and Shin Kaneko. The company’s lead program targets GPC3+ solid tumor cancers. Shinobi secured a $59M non-dilutive grant from the Japanese Agency for Medical Research and Development (AMED) to support that lead program. It also announced an extension of its Series A round, bringing total funding to $119M and adding investors Yosemite and Mitsubishi UFJ Capital. Shinobi has partnerships with Panasonic for scaled manufacturing and Anocca for TCR discovery and development and is led by CEO Dan Kemp. Shinobi Therapeutics is a biotechnology company based in San Francisco, CA and Kyoto, Japan developing a new class of immune-evasive iPSC-derived T cell therapies. The company has created an allogeneic CD8αβ iPS-T cell platform called Katana that demonstrates comprehensive immune evasion from all arms of the immune system. Its approach is based on research by scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at UCSF. Shinobi intends to use its newly raised funds to advance the Katana platform and progress its first program targeting GPC3+ solid tumor cancers toward the clinic. The company closed a $51M Series A financing to support those efforts. Shinobi is led by CEO Dan Kemp and focuses on developing off-the-shelf immune-evasive iPS-T cell therapies for solid tumors.

Total raised

$110M

Funding rounds

2

Latest round

Grant

Latest activity

Aug 2024